Nanotechnology Applications in Ischemic Stroke Therapy

Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, driven by the abrupt occlusion of cerebral arteries and ensuing oxygen and nutrient deprivation. Conventional therapies are constrained by narrow therapeutic windows, limited brain penetration and singular mechanisms of action. Nanotechnology offers multifaceted solutions by engineering particle size, surface chemistry and responsive architectures to traverse the blood–brain barrier, target pathological sites and modulate key injury cascades. Recent advances encompass antioxidant nanodots that scavenge reactive oxygen species (ROS), biomimetic carriers that exploit immune-cell homing, and adaptive platforms enabling sequential drug release in response to evolving microglial activity. These approaches combine neuroprotection, anti-inflammation and imaging guidance in a single construct, extending therapeutic windows, reducing infarct volumes and fostering neuronal recovery. By integrating diagnosis and therapy (“theranostics”), nanomedicines promise personalised and on-demand stroke interventions, with potential to transform acute care and rehabilitation in diverse healthcare settings.

Research from Nature Portfolio

Researchers have developed a pathogenesis-adaptive nanosystem based on polydopamine that offers sequential therapy for ischemic stroke. The intrinsic antioxidant properties of the polydopamine core neutralise ROS in the acute phase, while its mesostructure is engineered for enzyme-responsive release of minocycline when microglial overactivation arises. In vivo models demonstrate enhanced survival, reduced neuroinflammation and improved functional recovery compared with single-mode treatments, all without detectable systemic toxicity. Another seminal study reports transferrin-receptor-targeted selenium nanoparticles that localise to ischaemic regions and attenuate apoptosis, brain oedema and myelin loss in preclinical models. These biocompatible particles modulate metabolic and inflammatory signalling pathways, including mTOR and JAK2/STAT3, to promote tissue repair, suggesting a versatile platform for clinical translation.

Nanotechnology Applications in Ischemic Stroke Therapy publication trend

The graph below shows the total number of articles in nanotechnology applications in ischemic stroke therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): A selective endothelial interface that regulates molecular and cellular passage from blood to brain.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen that contribute to oxidative stress and cellular injury.

Microglia: Resident immune cells of the central nervous system that mediate inflammatory responses after injury.

Neutrophil hitchhiking: A delivery strategy in which nanoparticles bind to neutrophils to exploit their natural migration into inflamed brain tissue.

Polydopamine: A bioinspired synthetic polymer with redox-active functional groups used for antioxidant and adhesive properties.

Coordination polymer nanodot: An ultrasmall hybrid material formed by metal–organic coordination, offering high surface area and tunable reactivity.

References

1. Pathogenesis-adaptive polydopamine nanosystem for sequential therapy of ischemic stroke. Nature Communications (2023).
2. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Scientific Reports (2019).
3. Ultrasmall iron‐gallic acid coordination polymer nanodots with antioxidative neuroprotection for PET/MR imaging‐guided ischemia stroke therapy. Exploration (2023).
4. Ligustrazine Nanoparticle Hitchhiking on Neutrophils for Enhanced Therapy of Cerebral Ischemia‐Reperfusion Injury. Advanced Science (2023).